Ana Hećimović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ana Hećimović has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Irena Jukić
Croatian Institute of Transfusion Medicine, Petrova 3, 10000 Zagreb, Croatia
5 shared publications - Jasna Bingulac-Popovic
Croatian Institute of Transfusion Medicine, 10000 Zagreb, Croatia
2 shared publications - Maja Tomicic
Croatian Institute of Transfusion Medicine, Petrova 3, HR-10000 Zagreb, Croatia
2 shared publications - Manuela Miletić
Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia
2 shared publications - Miljana Stojić Vidović
Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia
2 shared publications - Tomislav Vuk
Quality Management Division Croatian Institute of Transfusion Medicine Zagreb Croatia
2 shared publications
Latest Publications
- Open Access
- 7 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 212
Pharmacokinetics of Snake Antivenom Following Intravenous and Intramuscular Administration in Envenomed Large Animal Model
Background: The parenteral administration of antivenoms is the mainstay in snakebite envenoming therapy. The standardized protocol does not exist, but it is agreed that the intravenous (i.v.) route is more effective than the others, especially the intramuscular (i.m.) route, based on the monitoring of venom/antivenom pharmacokinetics in the systemic circulation. Recent evidence suggests that the lymphatic system may be crucial in abolishing venom action. Methods: A preclinical study was performed to determine the optimal administration route with emphasis on venom/antivenom interplay in both the blood and lymph of experimentally envenomed sheep. Timed level measurements were used to compare the antivenom effect on the decrement of venom quantities in both relevant body compartments. Hematological and coagulation parameters, as well as proportions of developed anti-antivenom IgGs, were evaluated. Results: The i.m. antivenom resulted in faster and greater lymphatic absorption and complete neutralization of the venom, whereas the i.v. antivenom only slowed its absorption. The total amount of venom reaching the lymph (AUC0-t) was two times lower after i.m. administration. In the systemic circulation, i.m. antivenom had a lower peak concentration (cmax) and a longer time to reach it (tmax). However, the total venom exposure was three times lower than with i.v. antivenom. Irrespective of the treatment approach, both groups showed improvement in blood disorders with no significant difference in humoral response against equine F(ab’)2 fragments. Conclusions: I.m. administration proved to be a viable option for the snakebite management.
- 7 February 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (2) , 212
Open AccessPharmacokinetics of Snake Antivenom Following Intravenous and Intramuscular Administration in Envenomed Large Animal Model
Background: The parenteral administration of antivenoms is the mainstay in snakebite envenoming therapy. The standardized protocol does not exist, but it is agreed that the intravenous (i.v.) route is more effective than the others, especially the intramuscular (i.m.) route, based on the monitoring of venom/antivenom pharmacokinetics in the systemic circulation. Recent evidence suggests that the lymphatic system may be crucial in abolishing venom action. Methods: A preclinical study was performed to determine the optimal administration route with emphasis on venom/antivenom interplay in both the blood and lymph of experimentally envenomed sheep. Timed level measurements were used to compare the antivenom effect on the decrement of venom quantities in both relevant body compartments. Hematological and coagulation parameters, as well as proportions of developed anti-antivenom IgGs, were evaluated. Results: The i.m. antivenom resulted in faster and greater lymphatic absorption and complete neutralization of the venom, whereas the i.v. antivenom only slowed its absorption. The total amount of venom reaching the lymph (AUC0-t) was two times lower after i.m. administration. In the systemic circulation, i.m. antivenom had a lower peak concentration (cmax) and a longer time to reach it (tmax). However, the total venom exposure was three times lower than with i.v. antivenom. Irrespective of the treatment approach, both groups showed improvement in blood disorders with no significant difference in humoral response against equine F(ab’)2 fragments. Conclusions: I.m. administration proved to be a viable option for the snakebite management.
- 1 February 2020
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 27 (1) , 25-29
Warm red blood cell autoantibodies and clinical diagnoses in patients with or without autoimmune hemolysis
- 1 February 2020
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 27 (1) , 25-29
Warm red blood cell autoantibodies and clinical diagnoses in patients with or without autoimmune hemolysis
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 229-233
Estimation of the hepatitis E assay-dependent seroprevalence among Croatian blood donors
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 229-233
Estimation of the hepatitis E assay-dependent seroprevalence among Croatian blood donors
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 257-262
Anti-HBc prevalence among Croatian blood donors in a 14-year period (2004–2017): Assessment of trends, risks and need for implementing routine testing
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 257-262
Anti-HBc prevalence among Croatian blood donors in a 14-year period (2004–2017): Assessment of trends, risks and need for implementing routine testing
- Open Access
- 29 August 2018
- Published by IntechOpen
Heparin-Induced Thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT I) is a severe, life-threatening, and immunological drug reaction. According to the clinical-laboratory characteristics, there are two types of HIT: type I (HIT I) and type II (HIT II). HIT I is the result of non-immunologic, direct interaction of heparin with the platelet surface. Contrary, HIT II is immunologically induced (antibody-mediated) and life-threatening side effect of heparin therapy, often associated with thromboembolic complications. All patients receiving heparin are exposed to the development of anti-heparin antibodies, irrespective of the heparin dosage, type, and method of administration. HIT most commonly develops in intensive care patients, dialyzed patients, and cardiosurgical and orthopedic patients. It commonly develops after 5–10 days of heparin therapy. Platelet count decreases by more than 50% from the baseline and ranges from 20 × 109/L to 100 × 109/L. In HIT II, thromboembolic complications usually include deep-vein thrombosis and pulmonary embolism, but they also include arterial occlusion of the extremities, myocardial infarction, stroke, and necrosis and organ damage. Clinical assessment of the HIT probability using 4T´s score system, systematic monitoring of platelet number in heparin-receiving patients, and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the final confirmation of the diagnosis, enable timely administration of direct non-heparin thrombin antagonists, and reduce mortality from thromboembolic complications.
- 29 August 2018
- Published by IntechOpen
Open AccessHeparin-Induced Thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT I) is a severe, life-threatening, and immunological drug reaction. According to the clinical-laboratory characteristics, there are two types of HIT: type I (HIT I) and type II (HIT II). HIT I is the result of non-immunologic, direct interaction of heparin with the platelet surface. Contrary, HIT II is immunologically induced (antibody-mediated) and life-threatening side effect of heparin therapy, often associated with thromboembolic complications. All patients receiving heparin are exposed to the development of anti-heparin antibodies, irrespective of the heparin dosage, type, and method of administration. HIT most commonly develops in intensive care patients, dialyzed patients, and cardiosurgical and orthopedic patients. It commonly develops after 5–10 days of heparin therapy. Platelet count decreases by more than 50% from the baseline and ranges from 20 × 109/L to 100 × 109/L. In HIT II, thromboembolic complications usually include deep-vein thrombosis and pulmonary embolism, but they also include arterial occlusion of the extremities, myocardial infarction, stroke, and necrosis and organ damage. Clinical assessment of the HIT probability using 4T´s score system, systematic monitoring of platelet number in heparin-receiving patients, and specific laboratory diagnosis of anti-heparin antibodies substantially contribute to the final confirmation of the diagnosis, enable timely administration of direct non-heparin thrombin antagonists, and reduce mortality from thromboembolic complications.
- 11 April 2014
- Published by Wiley in Transfusion
- Vol. 54 (4) , 1200-1202
Wrong blood in tube error: first study on donor blood samples
- 11 April 2014
- Published by Wiley in Transfusion
- Vol. 54 (4) , 1200-1202
Wrong blood in tube error: first study on donor blood samples